2022
DOI: 10.1590/s1808-185120222101253789
|View full text |Cite
|
Sign up to set email alerts
|

Long-Term Use of Denosumab in Giant Cell Tumors and Vertebral Aneurysmal Bone Cysts

Abstract: Introduction: Denosumab is a human monoclonal antibody that binds to the receptor activator of nuclear factor kB (RANKL), it is used in the treatment of Osteoporosis. The Giant Cell Tumor (GCT) and the Aneurysmal Bone Cyst (ABC) use the same RANKL, and for this reason this drug began to be used for its treatment. There is consensus on the use, dose-time and 12-month duration for Denosumab treatment of GCT. Not so for ABC. In unresectable, disabling or recurrent tumors, its use could be for life. The adverse ev… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 21 publications
0
1
0
Order By: Relevance
“…In addition, complications, such as atypical femoral fractures may also occur [ 68 ]. Most serious complications occur in patients with unresectable tumors, owing to a long duration of treatment and high cumulative doses [ 100 , 101 ]. However, for PATD, the greatest risk remains LR, with the possibility of malignant transformation, which can lead to serious consequences.…”
Section: Dose and Duration Of Denosumab Therapy For Gctb Treatmentmentioning
confidence: 99%
“…In addition, complications, such as atypical femoral fractures may also occur [ 68 ]. Most serious complications occur in patients with unresectable tumors, owing to a long duration of treatment and high cumulative doses [ 100 , 101 ]. However, for PATD, the greatest risk remains LR, with the possibility of malignant transformation, which can lead to serious consequences.…”
Section: Dose and Duration Of Denosumab Therapy For Gctb Treatmentmentioning
confidence: 99%